©The Author(s) 2026.
World J Hepatol. Jan 27, 2026; 18(1): 113753
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.113753
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.113753
Figure 1 Flowchart representing patient evaluation and characterization in this retrospective cohort study.
1Standard eligibility criteria are body mass index > 40 kg/m2 or > 35 kg/m2 plus obesity-associated comorbidity. MASLD: Metabolic dysfunction-associated steatotic liver disease; BSE: Bariatric surgery eligible; BSNE: Bariatric surgery non-eligible; RYGB: Roux-en-Y gastric bypass; SG: Sleeve gastrectomy; MBSAQIP: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.
- Citation: Schwartz AW, Park EY, Ilagan-Ying YC, Zimmerman ZE, Bollinger B, Ying LD, Deng YD, Duffy AJ, Morton JM, Mehal WZ, Do A, Banini BA. Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study. World J Hepatol 2026; 18(1): 113753
- URL: https://www.wjgnet.com/1948-5182/full/v18/i1/113753.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i1.113753